TrialSignal transduction and targeted therapy2026

STRATEGIC-1: multiple-line, randomized, open-label GERCOR-PRODIGE-39 phase III trial in unresectable RAS/BRAF wild-type metastatic colorectal cancer.

Benoist Chibaudel et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.